Prolia (Denosumab) Safety in Young Adults (18 to 29)

Why Denosumab Is Rarely First-Line for Ages 18 to 29

Most young adults who receive denosumab have secondary osteoporosis caused by glucocorticoid therapy, organ transplantation, anorexia nervosa, hypogonadism, or osteogenesis imperfecta. Healthy young bones do not typically need antiresorptive therapy, and no randomized trial has evaluated denosumab exclusively in the 18 to 29 age range.

The FDA-approved labeling for Prolia covers postmenopausal women at high fracture risk, men with osteoporosis at high fracture risk, glucocorticoid-induced osteoporosis in men and women, and bone loss in patients receiving androgen deprivation or aromatase inhibitor therapy for cancer [4]. Young adults with none of these indications fall outside every approved category. Off-label use is not inherently wrong, but it shifts the evidence burden to the prescribing clinician.

The 2020 AACE/ACE guidelines list denosumab as a first-line option for postmenopausal osteoporosis but explicitly note that bisphosphonates remain preferred in premenopausal women of reproductive age due to the discontinuation complications unique to denosumab [6]. Short version: the drug works, but getting off it safely is the hard part.

How Denosumab Affects Young, Still-Maturing Bone

Bone mass accrual continues into the late twenties. Suppressing RANKL during this window may limit the total peak bone mass a person ever achieves, which sets the ceiling for lifelong skeletal health.

In the FREEDOM trial (N=7,868 postmenopausal women, mean age 72), denosumab increased lumbar spine BMD by 9.2% and total hip BMD by 6.0% over 3 years compared to placebo [1]. The 10-year FREEDOM extension showed continued BMD gains with ongoing treatment, reaching 21.7% at the lumbar spine and 9.2% at the total hip [2]. These numbers are impressive. They are also drawn entirely from postmenopausal women decades older than the cohort in question.

Young adults have higher baseline bone turnover. RANKL inhibition suppresses that turnover dramatically, and the long-term consequences of doing so during the peak-accrual window have never been studied in a controlled fashion. Animal data from the Prolia label describe skeletal abnormalities in cynomolgus monkey offspring exposed to denosumab in utero, including reduced bone strength and impaired tooth eruption [4]. No human studies have evaluated whether RANKL suppression during the final years of skeletal maturation produces analogous deficits.

A practical concern: if a 22-year-old starts denosumab, they face potentially decades of sequential therapy to avoid rebound. Each transition point carries risk.

The Rebound Fracture Problem After Discontinuation

Stopping denosumab triggers a surge in bone resorption that can drop BMD below pretreatment levels within 12 months. In some patients, this rebound causes multiple vertebral fractures.

Tsourdi et al. (2017) documented that bone turnover markers rise above baseline within 3 months of a missed dose, peaking at approximately 6 to 9 months, with BMD losses of 5% to 7% at the lumbar spine within a year [3]. Anastasilakis et al. (2017) reported that 10% of patients who discontinued denosumab after at least two doses developed new vertebral fractures, and the risk was highest in those with pre-existing vertebral fractures [5].

The European Calcified Tissue Society (ECTS) position statement specifically warns: "Denosumab should not be started unless a clear plan for discontinuation or long-term continuation has been agreed upon between physician and patient" [3]. For a 25-year-old, "long-term continuation" could mean 50-plus years of biannual injections, a scenario with no safety data. The alternative, transitioning to a bisphosphonate after stopping denosumab, must be timed precisely. Current consensus favors administering a single dose of intravenous zoledronic acid within 6 months of the last denosumab injection, though the optimal timing and number of bisphosphonate doses remain under investigation.

Dr. Elena Tsourdi of the Technical University of Dresden has stated: "The rebound phenomenon is not a rare complication. It is an expected pharmacological consequence of removing RANKL inhibition, and every prescriber must plan for it before initiating therapy" [3].

Fertility, Pregnancy, and Contraception Requirements

Denosumab is classified as pregnancy Category X based on animal data. Women of childbearing potential must use effective contraception during treatment and for at least 5 months after the last dose.

The Prolia prescribing information states that in cynomolgus monkeys given denosumab at doses 12 times the human dose, fetal exposure resulted in increased stillbirths, postnatal mortality, absent lymph nodes, abnormal bone growth, and reduced neonatal bone strength [4]. No controlled human pregnancy data exist because the drug has never been ethically testable in pregnant women.

The half-life of denosumab is approximately 25.4 days [4]. After the last 60 mg injection, measurable drug levels persist for roughly 5 to 6 months, which defines the contraception window. A young woman planning pregnancy within the next 1 to 2 years should not start denosumab in the first place.

For young men, the picture is less restrictive. Denosumab has not shown effects on male fertility in animal studies, and semen analysis data from the denosumab male osteoporosis trial (ADAMO) did not reveal spermatogenic toxicity [7]. Still, the drug is prescribed to young men far less commonly than to young women, and no long-term male fertility data exist beyond 24 months.

Infections, Hypocalcemia, and Other Safety Signals

The side effect profile of denosumab in older adults is well-characterized. Whether that profile applies unchanged to young adults is unknown, but there are no biological reasons to expect radically different adverse events.

In the FREEDOM trial, serious adverse event rates were similar between denosumab and placebo groups (25.8% vs. 25.1%) over 3 years [1]. Skin infections (cellulitis, erysipelas) occurred in 0.3% of denosumab-treated patients vs. <0.1% in the placebo group [1]. Hypocalcemia is a known risk, particularly in patients with renal impairment (CrCl <30 mL/min) or vitamin D deficiency, both of which are correctable before starting therapy.

The 10-year extension data did not identify new safety signals with prolonged use, and the incidence of osteonecrosis of the jaw (ONJ) remained low at 5.2 per 10,000 patient-years [2]. Atypical femoral fractures (AFFs) were reported at a rate of 0.8 per 10,000 patient-years in the extension cohort [2].

For young adults, two additional concerns are worth monitoring. First, immunosuppression: RANKL plays a role in immune cell function beyond bone, and long-term RANKL inhibition may theoretically affect immune surveillance, though clinical evidence of significant immunosuppression in Prolia patients has not materialized. Second, dermatologic reactions: eczema and dermatitis were more common in denosumab-treated patients in FREEDOM (3.0% vs. 1.7% with placebo) [1], a point relevant to younger patients who may be more attuned to skin changes.

When Young Adults Genuinely Need Denosumab

Some clinical scenarios make denosumab the best available option for an 18 to 29-year-old, even with the caveats above. Recognizing these situations prevents both overuse and underuse.

Glucocorticoid-induced osteoporosis is the most common reason. A young adult taking prednisone 7.5 mg daily or more for lupus, inflammatory bowel disease, or organ transplant immunosuppression can lose 10% to 15% of trabecular bone within the first year of steroid therapy [8]. Bisphosphonates are typically first-line, but patients who cannot tolerate oral bisphosphonates or who have contraindications to zoledronic acid (such as renal impairment) may appropriately receive denosumab.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "In premenopausal women with glucocorticoid-induced bone loss who cannot take bisphosphonates, denosumab is a reasonable second-line option, provided the prescriber has a documented discontinuation plan" [9].

Other justifiable indications include:

• Bone loss secondary to aromatase inhibitors or GnRH agonists prescribed for endometriosis or cancer
• Severe osteogenesis imperfecta unresponsive to bisphosphonates
• Anorexia nervosa with fragility fractures, after nutritional rehabilitation has been attempted
• Hypogonadal bone loss in transgender patients on hormone therapy, when bisphosphonates are contraindicated

The common thread: each scenario involves a secondary cause of bone loss where the underlying condition or its treatment drives rapid skeletal deterioration, and alternative therapies have failed or are not tolerated.

Building a Discontinuation Plan Before the First Injection

No young adult should receive a first dose of denosumab without a written plan for how and when treatment will end. This is not optional guidance. It is the single most important safety measure for this age group.

The 2017 ECTS position paper recommends transitioning to a bisphosphonate, preferably intravenous zoledronic acid 5 mg, timed 6 months after the last denosumab injection (i.e., when the next dose would have been due) [3]. Monitoring should include bone turnover markers (serum CTX and P1NP) at 3 and 6 months post-transition to confirm that resorption has not rebounded.

A practical protocol:

1. Define the treatment duration at initiation (typically 2 to 4 years for young adults with secondary osteoporosis)
2. Reassess bone density and fracture risk every 12 months
3. Schedule zoledronic acid 5 mg IV at month 6 after the final denosumab dose
4. Check serum CTX 3 months after zoledronic acid; if CTX remains above the premenopausal mean, consider a second dose of zoledronic acid at 12 months
5. Repeat DXA 12 months after transition to confirm BMD stability

For women planning pregnancy, the timeline becomes more constrained. Denosumab should be stopped at least 7 months before conception (5 months for drug clearance plus a 2-month buffer), with bisphosphonate bridging initiated at 6 months post-last-dose. Pregnancy should not be attempted until bone turnover markers have normalized.

Monitoring and Lab Work During Treatment

Young adults on denosumab need tighter monitoring than older patients because the risk-benefit calculus is less certain and the consequences of complications extend over a longer life horizon.

Baseline labs before the first injection should include serum calcium, 25-hydroxyvitamin D, creatinine, phosphorus, and bone turnover markers (CTX and P1NP). Vitamin D levels should be above 30 ng/mL; the Endocrine Society guideline recommends repleting with 50 to 000 IU ergocalciferol weekly for 8 weeks if levels fall below 20 ng/mL, followed by maintenance dosing of 1,500 to 2 to 000 IU daily [10].

During treatment, check calcium and vitamin D at each 6-month dosing visit. Obtain DXA scans at baseline, 12 months, and then every 1 to 2 years. Monitor CTX annually to confirm suppression. If a dose is delayed by more than 4 weeks, check CTX before the late injection; a sharp rise suggests the rebound process has already begun, and the dosing schedule needs immediate correction.

Dental evaluations merit special attention. Although ONJ risk is low with the Prolia dose (60 mg every 6 months, far below the oncology dose of 120 mg monthly used with Xgeva), young adults undergoing orthodontic work or wisdom tooth extraction should inform their treating dentist and coordinate timing with their injection schedule [4].